Sensorion (FR0012596468 – ALSEN) a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announced the appointment of Edwin Moses, former Chief Executive Officer of Ablynx, as Chairman of its Board of Directors.
Moses brings more than 25 years of executive experience as both CEO and Chairman of numerous life science companies, according to Sensorion’s announcement. He was Chairman and then CEO of Ablynx over 14 years, leading its growth from a small research-focused organization to one of Europe’s most successful biotechnology companies, listed on Euronext Brussels and NASDAQ, until its €3.9 billion (USD $4.4 billion) acquisition by Sanofi in 2018. Similarly, he led the growth, listing, and eventual sale of pharmaceutical services company Oxford Asymmetry International as CEO and later as Chairman between 1993-2001. Moses has raised more than €500 million (USD $563.6 million) in equity and debt financing and has negotiated multiple major collaborations with leading pharmaceutical companies. He currently is Chairman of Achilles Therapeutics Ltd, Avantium NV, and LabGenius Ltd, and is an Operating Partner at Keensight Capital.
Patrick Langlois, the outgoing Chairman of the Board, commented: “It is an extraordinary opportunity for Sensorion to have Edwin Moses as a Board Member. All members of Sensorion’s Board agree that Edwin’s outstanding experience and successful record will be of great benefit to the Company. On a personal basis, I was very much convinced that his expertise and potential contribution would also justify his appointment as Chairman of the Board, with immediate effect. I am confident, based on recent achievements, that Sensorion under the leadership of Edwin Moses and Nawal Ouzren will continue to emerge as a global leader in treating hearing loss.”
“Sensorion’s lead program SENS-401, in Phase 2 clinical testing, has promising potential to treat sudden sensorineural hearing loss, including that commonly experienced by soldiers after auditory trauma, as well as other forms of hearing loss,” said Moses. “Additionally, the notable partnership with Institut Pasteur, to discover and develop a wide range of gene therapies for rare hearing disorders, may help many people who currently have no satisfactory therapeutic options. I am truly excited to be taking on the role of Chairman at such an important time in the development of Sensorion and look forward to joining the exceptional scientific and business team supporting the Company on this exciting journey.”
“We are honored and delighted to welcome Edwin as Chairman of Sensorion,” said Nawal Ouzren, CEO of Sensorion. “He brings invaluable experience in all elements of leadership in the biotech industry, from research and clinical development to financing, regulatory approval, partnering, and M&A. His appointment further strengthens our leadership team and will add momentum to the development of our expanding hearing loss pipeline, including gene therapy for monogenic forms of hearing loss, as well as the clinical development of our lead product SENS-401 to treat sudden sensorineural hearing loss, for which we expect to report top-line Phase 2 clinical data in mid-2021.
“I would also like to extend my gratitude to Patrick Langlois for his dedicated service as Chairman of Sensorion over the last five years. Patrick’s knowledge and expertise have been important factors guiding the Company to this important transition. He leaves us in a strong position, and we wish him all the best for the future.”